A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy

Trial Profile

A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Atrophic vaginitis
  • Focus Therapeutic Use
  • Sponsors Peptonic Medical
  • Most Recent Events

    • 17 May 2017 Results from the exploratory part of this trial (n = 41) published in a Peptonic Medical media release.
    • 16 May 2017 According to a Peptonic Medical Media Release, Primary efficacy endpoints of the first part of this study, were not met.
    • 01 Feb 2017 According to a Peptonic Medical media release, all the randomized subjects of the first part of this trial have completed the treatment and exited the study. Out of 161 randomized subjects, more than 97 per cent of the subjects have completed the 12-week treatment and attended all of the follow-up visits during the course of the study. Company is analysing the data according to the study protocol and initial results are expected before end of March 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top